Résumé
Rivaroxaban is one of the new oral anticoagulants (NOACs) (recommended as reference treatments when a long-term anticoagulation is needed). It has many potential advantages in comparison with Vitamin K Antagonists (VKA). It has a predictable anticoagulant effect and does not theoretically require biological monitoring. It is also characterized by less food and drug interactions. However, due to major risks associated with over- and under-dosage, its optimal use in patients should be carefully followed by health care professionals. The aim of this article is to provide recommendations for pharmacists on the practical use of Xarelto® in its different approved indications. This document is adapted from the practical user guide of rivaroxaban which was developed by an independent group of Belgian experts in the field of thrombosis and haemostasis.
Titre traduit de la contribution | Rivaroxaban: Xarelto® - Recommendations for pharmacists |
---|---|
langue originale | Français |
Pages (de - à) | 28-36 |
Nombre de pages | 9 |
journal | Journal de Pharmacie de Belgique |
Numéro de publication | 1 |
Etat de la publication | Publié - 1 mars 2013 |
Empreinte digitale
Examiner les sujets de recherche de « Rivaroxaban (Xarelto®): Guide de la pratique officinale ». Ensemble, ils forment une empreinte digitale unique.Thèses de l'étudiant
-
Evaluation of thrombotic and/or bleeding risks associated with anticoagulotherapy.
Douxfils, J. (Auteur)Dogne, J.-M. (Promoteur), Mullier, F. (Promoteur), Masereel, B. (Président), Chatelain, B. (Jury), Chatelain, C. (Jury), Verhamme, P. (Jury), TEN CATE, H. (Jury) & Ageno, W. (Jury), 24 oct. 2015Student thesis: Doc types › Docteur en Sciences Biomédicales et Pharmaceutiques